TABLE 3.
Progression free survival for each time point for interventions that were significant compared to castratepre (shown as odds ratio and 95% confidence intervals).
| Time point | Control group | chemprept | Chempre | castratepretarget | Parp | Targetpre |
|---|---|---|---|---|---|---|
| 3 months | castratepre | 8.68 (4.09; 18.40) | 3.92 (2.58; 5.98) | 2.14 (1.21; 3.79) | 1.96 (1.09; 3.52) | - |
| prednisone | √ | √ | √ | √ | 1.52 (1.10; 2.09) | |
| 6 months | castratepre | 5.73 (2.54; 12.92) | 2.97 (1.73; 5.09) | 2.86 (1.36; 6.00) | 2.34 (1.36; 4.02) | - |
| prednisone | √ | √ | √ | √ | 1.52 (1.00; 2.30) | |
| 12 months | castratepre | × | 4.21 (1.16; 15.28) | 2.82 (1.14; 6.95) | 3.14 (1.86; 5.32) | - |
| prednisone | √ | √ | √ | √ | 1.73 (1.29; 2.31) | |
| 18 months | castratepre | × | × | × | 3.08 (1.67; 5.71) | - |
| prednisone | √ | √ | √ | √ | 1.45 (1.00; 2.09) |
Castratepre (Abiraterone or Enzalutamide + prednisone), prednisone, chemprept (cabazitaxel or docetaxel + carboplatin + prednisone), chempre (Docetaxel or Cabazitaxel + prednisone), castratepretarget(ipatasertib or tivantinib + abiraterone + predisone), parp (Olaparib or rucaparib), targetpre (buparlisib or Orteronel + prednisone).
√: the treatment on the top is significant compared to the control group on the left; ×: the treatment on the top is not significant compared to the Control group on the left.